Keep up to date with the latest research on this topic with citation updates for this article. Subscribe to citation updates Articles from other publishers (5) Cha Len Lee, Erika Martinez, Diego Malon Gimenez, Thiago Pimentel Muniz, Marcus Otho Butler & Samuel David Saibil. (2025) Female...
To date, pembrolizumab and nivolumab have both received FDA approval as second line monotherapies in the recurrent/metastatic setting. Pembrolizumab is a programmed death receptor-1 (PD-1) blocking antibody that was evaluated in a multicenter phase 1b clinical trial (KEYNOTE-012) for patients ...
The treatment was switched to budesonide, leading to a complete and definitive resolution of diarrhea. To date, budesonide has been stopped and pembrolizumab has not been restarted. Currently, there is a bone progression treated by radiotherapy alone. In case of a more important progression, a ...
We reported the most up-to-date efficacy and safety data from the trial. All the patients have been accrued to the trial. [We enrolled a] total of 35 patients with BCG-unresponsive, CIS-containing NMIBC. We followed 25 patients out to the 12-month mark, which is the primary end poi...
A Randomized, Double-Blind Study to Compare Efficacy, Pharmacokinetics, Safety, and Immunogenicity Between ABP 234 and Keytruda® (Pembrolizumab) in Subjects With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer The primary objective of this study is to compare the efficacy of ABP 23...
Subscribe to our e-Newsletters Stay up to date with the latest news, articles, and events. Plus, get special offers from American Pharmaceutical Review – all delivered right to your inbox!Sign up now! Adverse reactions occurring in patients with cSCC enrolled in KEYNOTE-62...
At 16 months follow‐up, four relapses and 2 deaths occurred, with PFS/OS of 82/97% at 18 months (Figure 1). In 22 tested pts to date, 55% had PDL‐1 tumor cell ≥ 30%, and PDL H‐score (a weighted average) was 0 in 3 pts, 1‐99 in 9 pts, and 100 or more in 10 ...
Of the 67 patients assigned to the placebo–chemotherapy group, 59 (88.1%) had ESCC, 36 (53.7%) had PD-L1 CPS ≥ 10, and 32 (47.8%) had ESCC PD-L1 CPS ≥ 10. Median follow-up, defined as the time from randomization to the data cutoff date, was 36.6 months (range, ...
Nonetheless, this data set represents, to our knowledge, the largest cohort of patients with DMPM treated with single-agent ICI to date and is the only such report combining patients from multiple centers. Conclusions In summary, these preliminary data suggest that pembrolizumab has clinical...
to targeted therapy, but this afforded a substantially lower 2-year RFS of 79%; partial responders had a 2-year RFS of 18%25. Recurrences with targeted therapy tended to occur late (>12–18 months)25, but still within 2 years26. With a median follow-up of 24.5 months, the ...